Morgan Stanley raised the firm’s price target on Phibro Animal Health (PAHC) to $21 from $20 and keeps an Equal Weight rating on the shares. The “broad-based beat” in fiscal Q3 and guidance raise “should lift the shares,” the analyst tells investors in a post-earnings note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PAHC:
- Phibro Animal Health: Balancing Strong EPS Growth with Cautious Hold Rating Amidst Flat Animal Health Performance
- Phibro Animal Health reports Q3 adjusted EPS 63c, consensus 52c
- Phibro Animal Health now sees FY25 adjusted EPS $1.96-$2.09, consensus $1.94
- Phibro Animal Health Declares Quarterly Cash Dividend
- PAHC Earnings Report this Week: Is It a Buy, Ahead of Earnings?